
    
      An open-label study with a single treatment arm involving 20 participants with progressive MS
      at multiple investigational study sites. After providing informed consent, participants
      meeting the inclusion and exclusion criteria will be randomized and approximately 4 weeks
      later will undergo a bone-marrow aspiration (BMA). Each participants will receive three
      Intrathecal cell transplantations within 16 weeks and will be followed for 12 weeks for
      safety and efficacy.
    
  